Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

57.16USD
2 Mar 2015
Change (% chg)

$0.14 (+0.25%)
Prev Close
$57.02
Open
$56.94
Day's High
$57.49
Day's Low
$56.50
Volume
1,217,696
Avg. Vol
785,588
52-wk High
$61.90
52-wk Low
$47.37

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva’s active pharmaceutical ingredient (API) business... (more)

Overall

Beta: 0.62
Market Cap(Mil.): $54,721.70
Shares Outstanding(Mil.): 956.55
Dividend: 0.35
Yield (%): 2.37

Financials

  TEVA.N Industry Sector
P/E (TTM): 16.03 38.87 40.17
EPS (TTM): 3.57 -- --
ROI: 8.76 16.97 16.27
ROE: 13.32 17.50 17.24
Search Stocks

Teva's internal investigation finds possible corruption

Feb 11 - Israeli drugmaker Teva Pharmaceutical Industries Inc said it found some business practices and transactions could violate the U.S. Foreign Corrupt Practices Act.

12 Feb 2015

UPDATE 1-Israeli drugmaker Teva eyes acquisitions after year of cuts

* Teva seeks growth markets, complex generics, specialty drugs

05 Feb 2015

BRIEF-Teva Pharm CEO on generic Copaxone in 2015

* There might not be any generic Copaxone competition in 2015 but we assume there may be -CEO Further company coverage: (Reporting By Steven Scheer)

05 Feb 2015

BRIEF-Teva Pharm plans 7 drug launches in 2015

* Plans 7 drug launches in 2015 with $400 million of new revenue -CEO Further company coverage: (Reporting By Tova Cohen)

05 Feb 2015

Teva Pharm Q4 profit, revenue meet expectations

TEL AVIV, Feb 5 - Teva Pharmaceutical Industries reported quarterly profit that met analysts' estimates on Thursday and reaffirmed its earnings forecast for the full year.

05 Feb 2015

BUZZ-India's Cipla surges to record high on generic Nexium supply hopes

** India's Cipla rises as much as 4.8 pct to record high of 710 rupees

27 Jan 2015

FDA approves Teva's generic version of AstraZeneca's Nexium

- The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug.

27 Jan 2015

UPDATE 1-FDA approves Teva's generic version of AstraZeneca's Nexium

Jan 26 - The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug.

27 Jan 2015

FDA approves Teva's generic version of AstraZeneca's Nexium

Jan 26 - The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's Nexium to treat acid reflux, the agency's first generic approval for the drug.

27 Jan 2015

REFILE-BRIEF-Natco Pharma says US Supreme Court remanded case relating to Teva's US patent to Court of Appeals

(Corrects dateline) Jan 21 - Natco Pharma Ltd : * The US supreme court has remanded case relating to Teva's US patent no

21 Jan 2015

Competitors

  Price Chg
Novartis AG (NOVN.VX) CHF95.60 -2.40
Biogen Idec Inc (BIIB.OQ) $415.79 --

Earnings vs. Estimates

Search Stocks